Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 EUR | 0.00% |
|
+7.80% | -36.83% |
28/05 | BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
16/04 | Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Environmental Services & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.83% | 56.35M | - | ||
+19.40% | 67.12M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BNN Stock
- BNN Stock
- Ratings BRAIN Biotech AG